The phrase "an ongoing randomized Phase" is correct and usable in written English.
It can be used in the context of clinical trials or research studies to describe a specific stage of the trial that is currently in progress and involves randomization.
Example: "The researchers are currently conducting an ongoing randomized Phase trial to evaluate the effectiveness of the new medication."
Alternatives: "a continuous randomized Phase" or "a current randomized Phase".
In this article we discuss the rationale and study design of an ongoing, randomized phase II study evaluating the role of amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) as a radiation protectant in patients receiving head and neck irradiation for lymphoma.
Cetuximab is currently being tested in an ongoing randomized phase III trial in Europe.
These results could have important clinical implication in current trials including an ongoing randomized phase II study of carboplatin/paclitaxel with or without T in patients with advanced or recurrent USC overexpressing HER2 (NCT01367002).
Knowledge regarding the choice of ALK inhibitors will also be expanded from an ongoing, randomized phase 3 trial (NCT02075840), head-to-head comparing alectinib with crizotinib in previously untreated patients with advanced ALK-rearranged NSCLC.
The FDA decision letter called for additional proof of clinical efficacy from an ongoing randomized Phase III trial (a new interim analysis of which is expected mid-2008) and more detailed information on the manufacturing process [ 15, 63].
In an ongoing, randomized Phase I/II study of eltrombopag versus placebo in patients with solid tumors receiving gemcitabine alone or in combination with cisplatin or carboplatin (NCT01147809), eltrombopag 100 mg daily is being administered according to a pre- and post-chemotherapy schedule (5 days before and 5 days following Day 1 of chemotherapy).
Herein we describe a companion ongoing randomized phase III study in patients with advanced nonsquamous non small-cell lunon small-celllung
Two already ongoing randomized phase III trials were required as postapproval commitments: A first-line study, comparing crizotinib to platinum doublet standard chemotherapy, and a second-line study, comparing crizotinib to either pemetrexed, or docetaxel.
Whether these agents will improve median OS in unselected patients will be determined by ongoing, randomized phase 3 trials.
This comparison provides preliminary data and highlights some of the variables to be considered in the ongoing randomized phase of the SCOUT trial.
The final results from the currently ongoing randomized Phase II study (NCT01395758) in KRAS-mutant NSCLC patients are eagerly awaited to verify if there is clinical benefit from the use of tivantinib and erlotinib in this unique patient subgroup.
